期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三氧化二砷联合沙利度胺治疗复发难治性多发性骨髓瘤临床研究 被引量：3

暂未订购
导出
摘要 目的探讨复发难治性多发性骨髓瘤的治疗方法。方法三氧化二砷10 mg/d,静脉滴注,每周用5 d,连用4周,间歇两周重复;维生素C 1000 mg/d,静脉滴注,三氧化二砷静脉滴注结束后15 min应用维生素C;28 d为1个疗程;沙利度胺100～200 mg/d,连续口服。结果 9例部分缓解,11例进步,总有效率71.4%;其中10例疾病维持在稳定期达12个月以上。三氧化二砷、沙利度胺治疗的副作用主要表现为疲劳、恶心、呕吐,轻度中性粒细胞减少,多数患者可耐受。结论三氧化二砷联合沙利度胺治疗复发难治性多发性骨髓瘤有效率较高,副作用较轻。
作者 王智 赵晓红 陆时运 周仲昊 宣旻
机构地区 江苏省无锡市第二人民医院
出处 《中国医学创新》 CAS 2010年第34期33-35,共3页 Medical Innovation of China
关键词 多发性骨髓瘤 三氧化二砷 沙利度胺 治疗
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Tosi P,Zamagni E,Cellini C,et al.Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.Haematologica,2002,87:408-414.
  • 2Dimopoulos M A,Hamilos G,Zomas A,et al.Pulsed cyclophosphamide,thalidomide and dexamethasone:an oral regimen for previously treated patients with multiple myeloma.Hematol J,2004,5:112-117.
  • 3Mohamad A,Hussein.Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.Oncologist,2002,7(Suppl1):20-29.
  • 4Laroche M,Brousset P,Ludot I,et al.Increased vascularization in myeloma.Eur J Haematol,2001,66:89-93.
  • 5Munshi N C.Arsenic trioxide:an emerging therapy for multiple myeloma.Oncologist,2001,6(Suppl2):17-21.
  • 6Munshi N C,Tricot G,Desikan R,et al.Clinical activity of arsenic trioxide for the treatment of m ultiple myeloma.Leukemia,2002,16:1835-1837.
  • 7Bahlis N J,McCafferty Grad J,Jordan McMurry I,et al.Feasibility and correlates of arsenic trioxide combined with ascorbic acidmediated depletion of intracellular glutathione for the treatment of re1apsed/refractory multiple myeloma.Clin Cancer Res,2002,8:3658-3668.
  • 8Vacca A,Ribattti D,Presta M,et al.Bone marrow neovascularization plasma cell angiogenic potential and matrix metallpproteinase-2 secretion paragression of human multiple myeloma.Blood,1999,93:3064-3073.
  • 9张海燕,李玉芳,管滨,孙桂珍.反应停对恶性血液病患者血清肿瘤坏死因子受体的影响及临床意义[J].临床血液学杂志,2004,17(5):261-262. 被引量：8
  • 10Davies F E,Rajenm H I,Deshim S T,et al.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood,2001,98:210-216.

二级参考文献16

  • 1Barlogie B, Zangari M, Spencer T, et al. Thalidomide in the management of multiple myeloma. Semin Hematol, 2001,38:250-259.
  • 2Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med,1999,341:1565-1571.
  • 3Rajkumar S V, Kyle R A. Angiogenesis in multiple myeloma. Semin Oncol, 2001,28:560-564.
  • 4Kneller A, Raanani P, Hardan I,et al. Therapy with thalidomide in refractory multiple myeloma patientsthe revival of an old drug. Br J Haematol, 2000,108:391-393.
  • 5Thompson M A,Witzig T E, Kumar S, et al. Plasma levels of tumor necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol,2003,123:305-308.
  • 6Salles G, Bienvenu J, Bastion Y, et al. Elevated circu lating levels of TNFa and its p55 solube receptor are associated with an adverse prognosis in lymphoma patients. BrJ Haematol, 1996, 93: 352-359.
  • 7Bark V. Nisman B, Polliack A, et al. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol ,1999, 62: 71-75.
  • 8Steins M B, Bieker R, Padro T, et al, Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma, 2003, 44: 1489-1493.
  • 9Deng L, Ding W, Granstein R D. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by langerhans. J Invest Dermatol, 2003, 121:1060-1065.
  • 10张勇,张一军.急性白血病患者血浆可溶性肿瘤坏死因子受体的测定及其临床意义[J].白血病,2000,9(5):274-276. 被引量：4

共引文献46

同被引文献31

引证文献3

二级引证文献8

中国医学创新
2010年 第34期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部